Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTHX1114 topical in healthy volunteers
NCT05769920Phase 1Completed
- Sponsor
- Trefoil Therapeutics
- Start
- Dec 2022
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of TTHX1114 in Corneal epithelial defect (4 arms), sponsored by Trefoil Therapeutics. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Dec 2022; status: completed.
02
Drugs
TTHX1114
03
Conditions
Corneal epithelial defect
Beyond the preview
Go deeper on NCT05769920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769920.